Blood metric ‘may predict survival’ in NSCLC brain metastases
In patients with non-small cell lung cancer brain metastases treated with immune-checkpoint inhibitors and upfront steroids, a low neutrophil-to-lymphocyte ratio may predict worse overall survival, US oncologists say.
Published in Scientific Reports, the team retrospectively investigated overall survival and intracranial progression-free survival in 171 patients with non-small cell lung cancer (NSCLC) with brain metastases treated with checkpoint inhibitors.